Cycle Checkpoint Abnormalities during Dementia: A Plausible Association with the Loss of Protection against Oxidative Stress in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: Increasing evidence suggests an association between neuronal cell cycle (CCL) events and the processes that underlie neurodegeneration in Alzheimer's disease (AD). Elevated levels of oxidative stress markers and mitochondrial dysfunction are also among early events in AD. Recent studies have reported the role of CCL checkpoint proteins and tumor suppressors, such as ATM and p53 in the control of glycolysis and oxidative metabolism in cancer, but their involvement in AD remains uncertain. METHODS AND FINDINGS: In this postmortem study, we measured gene expression levels of eight CCL checkpoint proteins in the superior temporal cortex (STC) of persons with varying severities of AD dementia and compare them to those of cognitively normal controls. To assess whether the CCL changes associated with cognitive impairment in AD are specific to dementia, gene expression of the same proteins was also measured in STC of persons with schizophrenia (SZ), which is also characterized by mitochondrial dysfunction. The expression of CCL-checkpoint and DNA damage response genes: MDM4, ATM and ATR was strongly upregulated and associated with progression of dementia (cognitive dementia rating, CDR), appearing as early as questionable or mild dementia (CDRs 0.5-1). In addition to gene expression changes, the downstream target of ATM-p53 signaling - TIGAR, a p53-inducible protein, the activation of which can regulate energy metabolism and protect against oxidative stress was progressively decreased as severity of dementia evolved, but it was unaffected in subjects with SZ. In contrast to AD, different CCL checkpoint proteins, which include p53, CHEK1 and BRCA1 were significantly downregulated in SZ. CONCLUSIONS: These results support the activation of an ATM signaling and DNA damage response network during the progression of AD dementia, while the progressive decrease in the levels of TIGAR suggests loss of protection initiated by ATM-p53 signaling against intensifying oxidative stress in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have reported alterations in DNA repair proteins (cell-cycle checkpoint proteins and tumor suppressors) of pathways involved in the repair of oxidative stress-induced lesions in patients with AD [28], [79].”
From Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease (2014) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 13×
“These findings suggest strong downregulation of TIGAR expression associated with measures of dementia severity but not conventional measures of AD neuropathology (NP density and Braak scores).”
MethodInfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
(2016) · Repository@Hull (Worktribe) (University of Hull) · doi:10.1111/j.1365 · Cited by 5,304
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase
Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., et al. (1995) · Science · doi:10.1126/science.7792600 · Cited by 2,785 · cited 2×
“Ataxia telangiectasia (A-T) is a human disease caused by ATM deficiency and characterized by the failure of CCL checkpoints, predisposition to cancer, immunodeficiency and by neurologic abnormalities caused by significant loss of neurons [34].”
BackgroundConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Self-citationTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 4×
“the loss of protection by the TP53-inducible survival signals [38].”
BackgroundInfluentialGene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“The specimen handling, neuropathology and diagnostic systems used for classifying human brains have been described extensively [65–67].”
MethodStewart, G. S., Maser, R. S., Stankovic, T., Bressan, D. A., Kaplan, M. I., Jaspers, N. G. J., Raams, A., Byrd, P. J., Petrini, J. H. J., & Taylor, A. M. R. (1999) · Cell · doi:10.1016/s0092-8674(00)81547-0 · Cited by 1,060
Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J.-J., Griffin, J. L., Wayland, M., Freeman, T., Dudbridge, F., Lilley, K. S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001511 · Cited by 971
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721
DNA Replication Precedes Neuronal Cell Death in Alzheimer's Disease
Yang, Y., Geldmacher, D. S., & Herrup, K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02661.2001 · Cited by 616
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · cited 1×
“from G1 phase through S, G2 and M phase to cell cycle exit at G0) and the process of neurodegeneration in AD [2–8].”
BackgroundCholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease
Yang, Y., Mufson, E. J., & Herrup, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02557.2003 · Cited by 483 · cited 3×
“Notably, these CCL events appear during early stages of disease [10,27].”
BackgroundAbnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.
McShea, A., Harris, P. L. R., Webster, K. R., Wahl, A. F., & Smith, M. A. (1997) · Europe PMC (PubMed Central) · Cited by 467
ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair
Cosentino, C., Grieco, D., & Costanzo, V. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.330 · Cited by 435
Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia
Middleton, F. A., Mirnics, K., Pierri, J. N., Lewis, D. A., & Levitt, P. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02718.2002 · Cited by 428
Herzog, K.-H., Chong, M. J., Kapsetaki, M., Morgan, J. I., & McKinnon, P. J. (1998) · Science · doi:10.1126/science.280.5366.1089 · Cited by 422
Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J. T.-J., Griffin, J. L., Wayland, M., Freeman, T., Dudbridge, F., Lilley, K. S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001532 · Cited by 375
Defective DNA Repair and Neurodegenerative Disease
Rass, U., Ahel, I., & West, S. C. (2007) · Cell · doi:10.1016/j.cell.2007.08.043 · Cited by 358 · cited 1×
“be exacerbated in dementia and AD [47–49].”
Cell cycle markers in the hippocampus in Alzheimer's disease
Nagy, Z., Esiri, M. M., Cato, A.-M., & Smith, A. D. (1997) · Acta Neuropathologica · doi:10.1007/s004010050665 · Cited by 318
Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease
de la Monte, S. M., Sohn, Y. K., & Wands, J. R. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00131-7 · Cited by 307
Haroutunian, V. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1185 · Cited by 289
Self-citationMechanisms of Neuronal Death in Alzheimer's Disease
Cotman, C. W., & Su, J. H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00878.x · Cited by 275
Aneuploidy and DNA Replication in the Normal Human Brain and Alzheimer's Disease
Mosch, B., Morawski, M., Mittag, A., Lenz, D., Tarnok, A., & Arendt, T. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0379-07.2007 · Cited by 271
Mitotic signaling by β‐amyloid causes neuronal death
COPANI, A., CONDORELLI, F., CARUSO, A., VANCHERI, C., SALA, A., STELLA, A. M. G., CANONICO, P. L., NICOLETTI, F., & SORTINO, M. A. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2225 · Cited by 245
Katsel, P., Li, C., & Haroutunian, V. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9297-x · Cited by 241
Self-citationp53 and Metabolism: Inside the TIGAR
Green, D. R., & Chipuk, J. E. (2006) · Cell · doi:10.1016/j.cell.2006.06.032 · Cited by 239
Neuronal apoptosis at the G1/S cell cycle checkpoint
Liu, D. X., & Greene, L. A. (2001) · Cell and Tissue Research · doi:10.1007/s004410100396 · Cited by 234 · cited 1×
“from G1 phase through S, G2 and M phase to cell cycle exit at G0) and the process of neurodegeneration in AD [2–8].”
BackgroundPei, J.-J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., & Cowburn, R. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00296-0 · Cited by 226 · cited 2×
“Additionally, ectopic sub-cellular redistribution of phosphorylated histone H3 [19], CDK11 (G2/M phase regulator) [20], phosphorylated retinoblastoma proteins [21] and CDK5 [22,23] has been found in AD affected neurons.”
BackgroundMaurer, I., Zierz, S., & Möller, H.-J. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00075-x · Cited by 221
KATSEL, P., DAVIS, K., & HAROUTUNIAN, V (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.007 · Cited by 221
Self-citationNeurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease
Haroutunian, V., Purohit, D. P., Perl, D. P., Marin, D., Khan, K., Lantz, M., Davis, K. L., & Mohs, R. C. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.713 · Cited by 201 · cited 2×
“A modified Bielschowsky method, as described previously [74] was used for neurofibrillary tangle staining and Braak staging.”
MethodSelf-citationIncreased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients
Mullaart, E., Boerrigter, M. E. T. I., Ravid, R., Swaab, D. F., & Vijg, J. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90542-8 · Cited by 201 · cited 1×
“be exacerbated in dementia and AD [47–49].”
A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains
Tseng, H.-C., Zhou, Y., Shen, Y., & Tsai, L.-H. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02934-4 · Cited by 198
Changes of p53 in the Brains of Patients with Alzheimer's Disease
Kitamura, Y., Shimohama, S., Kamoshima, W., Matsuoka, Y., Nomura, Y., & Taniguchi, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6301 · Cited by 185 · cited 1×
“damaged by neurodegeneration [51–53], we found no significant differences in TP53 gene expression in the STG, one of the most”
BackgroundPurohit, D. P., Perl, D. P., Haroutunian, V., Powchik, P., Davidson, M., & Davis, K. L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.205 · Cited by 185 · cited 1×
“[69].”
Self-citationEctopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?
Ogawa, O., Zhu, X., Lee, H.-G., Raina, A., Obrenovich, M. E., Bowser, R., Ghanbari, H. A., Castellani, R. J., Perry, G., & Smith, M. A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0684-3 · Cited by 175
Yang, Y., Varvel, N. H., Lamb, B. T., & Herrup, K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3707-05.2006 · Cited by 173
Zindy, F., Cunningham, J. J., Sherr, C. J., Jogal, S., Smeyne, R. J., & Roussel, M. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13462 · Cited by 172
Barley, K. M., Dracheva, S. M., & Byne, W. M. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.04.019 · Cited by 171
p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells
Hooper, C., Meimaridou, E., Tavassoli, M., Melino, G., Lovestone, S., & Killick, R. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.026 · Cited by 165
Neuronal cell cycle re-entry mediates Alzheimer disease-type changes
McShea, A., Lee, H.-G., Petersen, R. B., Casadesus, G., Vincent, I., Linford, N. J., Funk, J.-O., Shapiro, R. A., & Smith, M. A. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.09.010 · Cited by 165
Role of the neuropathology of Alzheimer disease in dementia in the oldest-old
Haroutunian, V., Schnaider-Beeri, M., Schmeidler, J., Wysocki, M., Purohit, D. P., Perl, D. P., Libow, L. S., Lesser, G. T., Maroukian, M., & Grossman, H. T. (2008) · Archives of Neurology · doi:10.1001/archneur.65.9.1211 · Cited by 154
Self-citationVariations in differential gene expression patterns across multiple brain regions in schizophrenia
Katsel, P., Davis, K. L., Gorman, J. M., & Haroutunian, V. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.03.020 · Cited by 143
Self-citationTranscriptional vulnerability of brain regions in Alzheimer's disease and dementia
Haroutunian, V. H., Katsel, P., & Schmeidler, J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.021 · Cited by 142
Self-citationCell Cycle Activation and Aneuploid Neurons in Alzheimer's Disease
Arendt, T. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8262-0 · Cited by 141
Chen, Y., McPhie, D. L., Hirschberg, J., & Neve, R. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8929 · Cited by 137
Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest
Girard, P.-M., Riballo, E., Begg, A. C., Waugh, A., & Jeggo, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205596 · Cited by 123 · cited 1×
“checkpoint mechanism that ensures DNA integrity and repair [35,43–45].”
BackgroundKi-67 Immunoreactivity in Alzheimerʼs Disease and Other Neurodegenerative Disorders
SMITH, T. W., & LIPPA, C. F. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199505000-00002 · Cited by 117
A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT
Ekins, S., Andreyev, S., Ryabov, A., Kirillov, E., Rakhmatulin, E. A., Sorokina, S. Y., Bugrim, A. E., & Nikolskaya, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008458 · Cited by 117
Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons
Zhang, J., Cicero, S. A., Wang, L., Romito-DiGiacomo, R. R., Yang, Y., & Herrup, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711355105 · Cited by 113
Katsel, P., Davis, K. L., Li, C., Tan, W., Greenstein, E., Hoffman, L. B., & Haroutunian, V. H. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.19 · Cited by 109
Self-citationEstimating the validity of the Clinical Dementia Rating Scale: The CERAD experience
Fillenbaum, G. G., Peterson, B. L., & Morris, J. C. (1996) · Aging Clinical and Experimental Research · doi:10.1007/bf03339599 · Cited by 108
A variable fold‐change threshold determines significance for expression microarrays
Mariani, T. J., Budhraja, V., Mecham, B. H., Gu, C. C., Watson, M. A., & Sadovsky, Y. (2003) · The FASEB Journal · doi:10.1096/fj.02-0351fje · Cited by 108
Fillenbaum, G. G., Beekly, D. L., Edland, S. D., Hughes, J. P., Heyman, A., & van Belle, G. (1997) · PubMed · Cited by 103
The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1
Yurov, Y. B., Iourov, I. Y., Vorsanova, S. G., Ia, D., Kravetz, V. S., Beresheva, A. K., Kolotii, A. D., Monakchov, V. V., Uranova, N. A., Vm, V., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.035 · Cited by 103
Increased p27, an essential component of cell cycle control, in Alzheimer's disease
Ogawa, O., Lee, H., Zhu, X., Raina, A., Harris, P. L. R., Castellani, R. J., Perry, G., & Smith, M. A. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00042.x · Cited by 96
Haroutunian, V., Katsel, P., Dracheva, S., & Davis, K. L. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.10.1834 · Cited by 92
Self-citationYurov, Y. B., Vm, V., Vorsanova, S. G., Monakhov, V. V., & Iourov, I. Y. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00363-1 · Cited by 90
Shiloh, Y., & Rotman, G. (1996) · Journal of Clinical Immunology · doi:10.1007/bf01541389 · Cited by 87
The Clinical Dementia Rating scale: Community-based validation of `profound' and `terminal' stages
Dooneief, G., Marder, K., Tang, M.-X., & Stern, Y. (1996) · Neurology · doi:10.1212/wnl.46.6.1746 · Cited by 86
Computational prediction of human drug metabolism
Ekins, S., Andreyev, S., Ryabov, A., Kirillov, E., Rakhmatulin, E. A., Bugrim, A., & Nikolskaya, T. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.2.303 · Cited by 86
Bonda, D. J., Evans, T. A., Santocanale, C., Llosá, J. C., Viňa, J., Bajic, V. P., Castellani, R. J., Siedlak, S. L., Perry, G., Smith, M. A., et al. (2009) · Aging · doi:10.18632/aging.100044 · Cited by 83
DNA Fragmentation Decreased in Schizophrenia but Not Bipolar Disorder
Benes, F. M., Walsh, J., Bhattacharyya, S., Sheth, A., & Berretta, S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.359 · Cited by 82
Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia
Kerns, D. C., Vong, G. S., Barley, K. M., Dracheva, S. M., Katsel, P., Casaccia, P., Haroutunian, V. H., & Byne, W. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.012 · Cited by 81
Self-citationDomenico, F. D., Cenini, G., Sultana, R., Perluigi, M., Uberti, D., Memo, M., & Butterfield, D. A. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9924-9 · Cited by 77
Neuronal binucleation in Alzheimer disease hippocampus
Zhu, X., Siedlak, S. L., Wang, Y., Perry, G. L., Castellani, R. J., Cohen, M. L., & Smith, M. A. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00908.x · Cited by 69
BRCA1 May Modulate Neuronal Cell Cycle Re-Entry in Alzheimer Disease
Evans, T. A., Raina, A. K., Delacourte, A., Aprelikova, O., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2007) · International Journal of Medical Sciences · doi:10.7150/ijms.4.140 · Cited by 67
Chen, J., Cohen, M. L., Lerner, A. J., Yang, Y., & Herrup, K. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-60 · Cited by 64
Zhu, X., McShea, A., Harris, P. L. R., Raina, A. K., Castellani, R. J., Funk, J. O., Shah, S., Atwood, C., Bowen, R., Bowser, R., et al. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20028 · Cited by 63
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB–E2F1 complex
Madan, E., Gogna, R., Kuppusamy, P., Bhatt, M., Pati, U., & Mahdi, A. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.260 · Cited by 61
Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes
Harris, P. L. R., Zhu, X., Pamies, C., Rottkamp, C. A., Ghanbari, H. A., McShea, A., Feng, Y., Ferris, D. K., & Smith, M. A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00218-9 · Cited by 58
Benes, F. M., Lim, B., & Subburaju, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903066106 · Cited by 55
Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals
Katsel, P., Tan, W., & Haroutunian, V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007642 · Cited by 55
Self-citationRukhsana Sultana, A., & Butterfield, D. A. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9123-x · Cited by 52
Thakur, A., Siedlak, S. L., James, S. L., Bonda, D., Rao, A., Webber, K. M., Camins, A., Pallàs, M., Casadesús, G., Lee, H., et al. (2008) · PubMed · Cited by 45
Budhraja, V., Spitznagel, E. L., Schaiff, W. T., & Sadovsky, Y. (2003) · BMC Biology · doi:10.1186/1741-7007-1-1 · Cited by 45
Herrup, K. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e527 · Cited by 44
Herrup, K. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/527 · Cited by 38
Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer’s Disease
Uberti, D., Lanni, C., Racchi, M., Govoni, S., & Memo, M. (2008) · Neurodegenerative Diseases · doi:10.1159/000113704 · Cited by 34
Bajić, V., Su, B., Lee, H., Kudo, W., Siedlak, S. L., Živković, L., Spremo‐Potparević, B., Djelić, N., Milićević, Z., Singh, A., et al. (2011) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-011-0011-2 · Cited by 28
Kallhoff, V., Hu, L., Chen, X., Pautler, R. G., & Zheng, H. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2873-08.2008 · Cited by 17
Increased Expression of p130 in Alzheimer Disease
Previll, L. A., Crosby, M. E., Castellani, R. J., Bowser, R. P., Perry, G. L., Smith, M. A., & Zhu, X. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9146-3 · Cited by 16
Effects of Cell Cycle Inhibitors on Tau Phosphorylation in N2aTau3R Cells
Conejero‐Goldberg, C., Townsend, K. P., & Davies, P. J. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9044-z · Cited by 15
Sourlingas, T. G., Issidorides, M. R., Alevizos, B., Kontaxakis, V. P., Chrysanthou‐Piterou, M., Livaniou, E., Karpouza, A., & Sekeri‐Pataryas, K. E. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00041-6 · Cited by 12
Cited by
Myelination, oligodendrocytes, and serious mental illness
Haroutunian, V., Katsel, P., Roussos, P., Davis, K. L., Altshuler, L. L., & Bartzokis, G. (2014) · Glia · doi:10.1002/glia.22716 · Cited by 248
Self-citationp53 and mitochondrial function in neurons
Wang, D. B., Kinoshita, C., Kinoshita, Y., & Morrison, R. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.015 · Cited by 167
Tewari, D., Stankiewicz, A. M., Mocan, A., Sah, A. N., Tzvetkov, N. T., Huminiecki, Ł., Horbańczuk, J. O., & Atanasov, A. G. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00003 · Cited by 148
X chromosome aneuploidy in the Alzheimer’s disease brain
Yurov, Y. B., Vorsanova, S. G., Liehr, T., Kolotii, A. D., & Iourov, I. Y. (2014) · Molecular Cytogenetics · doi:10.1186/1755-8166-7-20 · Cited by 140
Connecting the dots between tau dysfunction and neurodegeneration
Frost, B., Götz, J., & Feany, M. B. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.005 · Cited by 124
“Mechanism Potential Targets Drug Effort Tau Hyperphosphorylation/Misfolding PAR-1* GSK-3β* HSPs* Lithium Methylene Blue Tideglusib** Nicotinomide** Valproic Acid** LMT-X** Sodium Selenate** Compound A* Thiamet-G* SNR-003-556* Tau Spread HSPGs MC1 Antibody * PHF1 Antibody* Synapse Loss STEP NMDAR Fyn MEM 1003 Neramexan…”
BackgroundInfluential
Metadata
- Authors
- Katsel, P., Tan, W., Fam, P., Purohit, D. P., & Haroutunian, V.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- James J. Peters VA Medical Center (US)
- Corresponding author
- Katsel, Pavel
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-07-05
- Volume
- 8
- Issue
- 7
- Pages
- e68361
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3702571
- OpenAlex
- W1972266320
- Cited by
- 52
- References
- 89
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 8 · 2014: 7
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-07-17)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Leir Foundation
- National Institutes of Health (MH066392, AG05138, AG02219)
- National Institute on Aging (P50 AG 05138, P01 AG 02219, P50AG005138, P01AG002219)
- National Institute of Mental Health (P50MH066392, MH066392, R01MH064673, MH-064673)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- Alzheimer's disease, dementia, cell cycle checkpoint proteins, oxidative stress, ATM signaling, p53, DNA damage response, TIGAR, MDM4, ATR, Chk1, BRCA1, superior temporal cortex, mitochondrial dysfunction, schizophrenia, gene expression, neurodegeneration
- MeSH terms
- Alzheimer Disease, Autopsy, Dementia, DNA Damage, Humans, Phosphoric Monoester Hydrolases, Temporal Lobe, Oxidative Stress, Disease Progression, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Gene Regulatory Networks, Cell Cycle Checkpoints, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.